The ever-volatile biotech sector is making noise today. Viking Therapeutics Inc (NASDAQ:VKTX) is soaring up the charts, while Intellia Therapeutics Inc (NASDAQ:NTLA) stumbles.Viking Could Burn Shorts' ShipVKTX is up 24% to trade at $74.75 today, after the company's third-quarter loss came in below analyst estimates. The big driver though is the encouraging pipeline update on its obesity drug, which showed promising results in clinical studies. This is even more notable considering Viking doesn't have an app ...

New data to be presented will include biomarkers of disease progression and functional capacity from the ongoing Phase 1 study of nex-z, an investigational in vivo CRISPR gene editing therapy for ATTR amyloidosis CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that interim data from the ongoing Phase 1 study of nexiguran ziclumeran (nex ...

Group 1: Ark Invest Portfolio Strategy - Ark Invest, led by Cathie Wood, focuses on aggressive investments in growth businesses pursuing disruptive innovation [1][2] - The portfolio recently increased its holdings in two biotech stocks, indicating a belief in their potential for success despite inherent risks [1][2] Group 2: Intellia Therapeutics - Intellia Therapeutics is a gene-editing biotech aiming to treat inherited rare diseases by editing dysfunctional genes [3][4] - The company has a late-stage program for transthyretin (ATTR) amyloidosis entering phase 3 trials and a mid-stage program for hereditary angioedema (HAE) with upcoming data [4][5] - Financially, Intellia reported approximately $940 million in cash and equivalents, with R&D expenses of about $449 million, providing a runway until late 2026 [5] - Risks include potential scientific or regulatory hurdles that could significantly impact the company's value [6][7] Group 3: Recursion Pharmaceuticals - Recursion Pharmaceuticals holds a focus on using artificial intelligence (AI) in drug development, with a pipeline of therapies for rare diseases [8][9] - The company is merging with Exscientia, expected to close in early 2025, which will enhance its cash position and oncology pipeline [9][10] - The merged entity will have around $850 million in cash and is projected to achieve $100 million in efficiencies post-transaction [10] - The new company anticipates up to 10 clinical data readouts in the next 18 months, presenting potential catalysts for stock movement [10][11] - Collaborations with major biopharma companies like Merck, Roche, and Nvidia suggest confidence in Recursion's future prospects [12][13]

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there. Intellia Therapeutics (NASDAQ: NTLA ) is one of the vanguard of companies that is attempting to convert the amazing and Nobel Prize winning technology of CRISPR/Cas9 into ...

Intellia Therapeutics, Inc. (NTLA) incurred second-quarter 2024 loss of $1.31 per share (excluding a one-time expense of change in fair value of investments), which was wider than the Zacks Consensus Estimate of a loss of $1.21. In the year-ago quarter, Intellia had incurred a loss of $1.40 per share. Including the above one-time expense, the company reported a loss of $1.52 per share in the second quarter of 2024. The company's total revenues currently comprise only collaboration revenues. NTLA reported re ...

| --- | --- | --- | --- | --- | --- | |--------------------|-------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | Intellia | is Leading the | | | | | | | Gene Editing Revolution | | | | | | | | | | | | | Corporate Overview | | | | | | | August 2024 | | | | | | | | | | | | | Intellia Therapeutics' Legal Disclaimer 2 This presentation contains "forward-looking statements" of Intellia Therapeutics, Inc. ("Intellia", "we" or "our") within the meaning of the Private Securities ...

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.21. This compares to loss of $1.40 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.26%. A quarter ago, it was expected that this company would post a loss of $1.35 per share when it actually produced a loss of $1.06, delivering a surprise of 21.48%. Over the last four quarters, the compan ...

Phase 2 study of NTLA-2002 for hereditary angioedema (HAE) met its primary and all secondary endpoints; plan to present detailed results at an upcoming medical meeting in the fourth quarter Selected the 50 mg dose of NTLA-2002 for the pivotal Phase 3 trial on track to begin in 2H 2024 Rapid enrollment continues in the Phase 3 MAGNITUDE trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy On track to initiate the Phase 3 study of NTLA-2001 for the treatment of heredita ...

As a rule of thumb, you want to make market decisions based on a wide range of assessments and not just on the recommendation of a popular investor. That said, if you had to trade with a particular individual, you can do a lot worse than so-called Cathie Wood stocks. An entrepreneur and a tech visionary, Wood is considered a star stock picker. She's the founder of ARK Invest, which features around $60 billion worth of assets. Part of the reason for considering the ideas she supports is longevity. Wood has b ...

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2024 financial results and operational highlights in a conference call on August 8, 2024, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participan ...